Chardan Capital Reiterates Buy Rating for Immuneering (NASDAQ:IMRX)
Chardan Capital reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a research report report published on Monday,Benzinga reports. They currently have a $13.00 target price on the stock. IMRX has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price […]
Chardan Capital reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a research report report published on Monday,Benzinga reports. They currently have a $13.00 target price on the stock. IMRX has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price […]
